The Lp(a) Journey
Professor Henry Ginsberg, Co-Chair of the Lp(a) Forum, looks at progress in Lp(a) science that has led to multiple Lp(a) targeting agents in development.
The Unanswered Questions
Professor John Chapman, Co-Chair of the Lp(a) Forum, considers key questions about Lp(a) atherogenicity, including the heterogeneity of the Lp(a) proteome and lipidome.
Who’s who in the Lp(a) proteome?
Professor Sally McCormick, University of Otago, New Zealand, discusses key research that has provided important insights into the role of the Lp(a) proteome.
2nd Closed Scientific Expert Meeting of the Editorial Board
See more
One size fits all? Does the same Lp(a) concentration confer the same cardiovascular risk across ethnicities?
Professor Keith Ferdinand, Tulane University School of Medicine, New Orleans, USA, discusses the clinical implications for differences in Lp(a) concentration across ethnicities.
Is Lp(a)-associated cardiovascular risk independent of that associated with LDL-C?
Professor Sam Tsimikas, University of California San Diego, USA, considers the evidence supporting Lp(a) as an independent risk factor for atherosclerotic cardiovascular disease.
HORIZON cardiovascular outcome trial
Professor Steven Nissen, Cleveland Clinic, Ohio, USA, provides an update of the HORIZON trial – the first study due to report results of Lp(a) reduction on cardiovascular outcomes.
Educational Partners and Supporters
(Founding Partner)
Novartis has provided with arm’s length sponsorship towards the set-up of the Lp(a) Forum. The content was developed independently by the Forum.
